Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Reiterated by HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report released on Friday, Benzinga reports. They presently have a $400.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 51.84% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Chardan Capital reaffirmed a “buy” rating and set a $225.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, May 3rd. TD Cowen lifted their price target on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. Evercore ISI boosted their target price on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a report on Tuesday, June 25th. Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the stock a “buy” rating in a report on Tuesday, June 25th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, June 24th. Seven analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $278.59.

Alnylam Pharmaceuticals Stock Down 8.2 %

Shares of NASDAQ:ALNY traded down $23.57 during midday trading on Friday, hitting $263.44. The stock had a trading volume of 2,494,305 shares, compared to its average volume of 894,244. The company’s 50-day moving average price is $254.02 and its 200-day moving average price is $186.86. The company has a market capitalization of $33.32 billion, a P/E ratio of -97.80 and a beta of 0.37. Alnylam Pharmaceuticals has a fifty-two week low of $141.98 and a fifty-two week high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million during the quarter, compared to analyst estimates of $447.22 million. Alnylam Pharmaceuticals’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($2.21) earnings per share. Research analysts expect that Alnylam Pharmaceuticals will post -3.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $276,726.02. Following the transaction, the executive vice president now owns 14,181 shares in the company, valued at $3,275,669.19. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the sale, the chief executive officer now owns 80,534 shares in the company, valued at approximately $18,602,548.66. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $276,726.02. Following the completion of the sale, the executive vice president now owns 14,181 shares of the company’s stock, valued at approximately $3,275,669.19. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 103,148 shares of company stock worth $25,658,824. Insiders own 1.50% of the company’s stock.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ALNY. Allspring Global Investments Holdings LLC grew its position in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the period. Ashton Thomas Private Wealth LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at about $26,000. Altitude Crest Partners Inc. bought a new position in Alnylam Pharmaceuticals during the first quarter worth about $30,000. Robeco Institutional Asset Management B.V. boosted its position in Alnylam Pharmaceuticals by 155.7% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares during the period. Finally, GAMMA Investing LLC bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth about $52,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.